271 Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages

• Peter Probst,
• Huyen Dinh,
• Sam Lam,
• Valerie Wall,
• Darbie Whitman,
• Tom Graddis,
• Myriam Bouchlaka,
• Randi Simmons,
• Meghan Zuck,
• Ray Fox,
• Kamal Puri

Affiliations

Peter Probst

2Kineta, Inc., Seattle, WA, USA

Huyen Dinh

OncResponse Inc., Seattle, WA, USA

Sam Lam

OncResponse Inc., Seattle, WA, USA

Valerie Wall

OncResponse Inc., Seattle, WA, USA

Darbie Whitman

OncResponse Inc., Seattle, WA, USA

Tom Graddis

OncResponse Inc., Seattle, WA, USA

Myriam Bouchlaka

OncResponse Inc., Seattle, WA, USA

Randi Simmons

OncResponse Inc., Seattle, WA, USA

Meghan Zuck

OncResponse Inc., Seattle, WA, USA

Ray Fox

OncResponse Inc., Seattle, WA, USA

Kamal Puri

OncResponse Inc., Seattle, WA, USA